Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study

作者：Alison R. Sehgal, Daanish Hoda, Peter A. Riedell, Nilanjan Ghosh, Mehdi Hamadani, Gerhard Carl Hildebrandt, John E. Godwin, Patrick Michael Reagan, Nina D. Wagner‐Johnston, James H. Essell, Rajneesh P. Nath, Scott R. Solomon, Rebecca Champion, Edward J. Licitra, Suzanne R. Fanning, Neel K. Gupta, Ronald L. Dubowy, Aleco D’Andrea, Lei Wang, Ken Ogasawara, Jerill Thorpe, Leo I. Gordon · 发表于：The Lancet Oncology · 年份：2022 · DOI：10.1016/s1470-2045(22)00339-4 · 被引用次数：242 · 研究领域：CAR-T cell therapy research、Lymphoma Diagnosis and Treatment、Cancer Immunotherapy and Biomarkers